Company intelligence / Profile preview

Zalgen Labs

Frederick, Maryland, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Zalgen Labs develops and supplies recombinant viral antigens, monoclonal antibodies, and immunodiagnostic kits (e.g., for Lassa fever, Ebola, SARS‑CoV‑2) and is advancing a structure-guided, preclinical bivalent vaccine program targeting Lassa virus and Ebola virus in collaboration with academic and global health partners.[2][3][4][5]

Therapeutic areas: Infectious Diseases
Modalities: VaccineProteinRecombinant proteinMonoclonal antibodyDiagnostic kitDevice
Industry: Biotech

Drug pipeline

1 asset

arevirumab-3

Preclinical

Partnerships

Coalition for Epidemic Preparedness Innovations (CEPI)[2][4]VHFC (Viral Hemorrhagic Fever Consortium) partners, including Tulane University[2]NIH/NIAID (funding and collaborative vaccine development support)[2]

Beyond the preview

Go deeper on Zalgen Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zalgen Labs.

Explore the full profile